ERBB2 and breast cancer: The cytolytic activity of 89Zr-NK cells (24 h after radiolabeling) and unlabeled NK cells, from 4 healthy human donors, was assessed in ADCC assays using trastuzumab and HER2-positive breast cancer cell lines SKBR3 and HCC1954 (Fig. 2).